{"title": "Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection - Full Text View - ClinicalTrials.gov", "author": null, "url": "https://clinicaltrials.gov/ct2/show/NCT04251871", "hostname": "clinicaltrials.gov", "description": "Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection - Full Text View.", "sitename": "ClinicalTrials.gov", "date": "2020-02-05", "cleaned_text": "Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection | The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our | |ClinicalTrials.gov Identifier: NCT04251871| | | Recruitment Status : Unknown Verified May 2020 by Xiaohe Xiao, Beijing 302 Hospital. Recruitment status was: Recruiting First Posted : February 5, 2020 Last Update Posted : May 5, 2020 - Study Details [Tabular View](/ct2/show/record/NCT04251871) [No Results Posted](/ct2/show/results/NCT04251871) |Pneumonia Caused by Human Coronavirus (Disorder)||Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules Drug: Conventional medicines (Oxygen therapy, alfa interferon via COVID-19 Infection: A Perspective, Open-labeled, Randomized, Trial| |Actual Study Primary Date :||January TCMs granules | Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days. Traditional Chinese Medicines (TCMs) granules: one bag, p.o, bid, for 14 days. | Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules | Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) Chinese Medicines (TCMs) granules: 20g, p.o, bid, for 14 days. | Active Comparator: Conventional medicines | Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days. | Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) | Conventional medicines: oxygen therapy, antiviral (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days. - The incidents of acute respiratory distress syndrome (ARDS) development [ Time Frame: 14 days ]The incidence rate of acute respiratory distress syndrome (ARDS) development - The time to fever resolution rate [ Time Frame: 14 days ]Time to complete remission of fever in eligible subjects - Time to recovery of lung injury [ Time Frame: 14 days ]improvement of chest radiographic evidence indirectly reflects recovery in patients infected with COVID-19. - Rate of subjects who die [ Time Frame: 28 days ]The rate of subject who die will be described. - Rate of subjects receiving systematic corticosteroids [ Time Frame: 28 days ]The rate of subjects with severe 2019-nCoV infection who receive systematic corticosteroids will be described. - The length of hospital stays [ Time Frame: 28 days ]The length of hospital stays - The duration of respiratory support [ Time Frame: 28 days ]The duration of respiratory support including invasive and non-invasive mechanical ventilation Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, [Learn About Clinical Studies.](/ct2/about-studies/learn) |Ages Eligible for Study:||14 Years to 80 Years (Child, Adult, Older Adult)| |Sexes Eligible for Study:||All| |Accepts Healthy Volunteers:||No| Inclusion Criteria: - Confirmed COVID-19 infection case in term of laboratory evidence; - 80 years age 14years; - Within 72 hours after the onset of abnormalities shown by Chest radiology or several symptoms (fever and cough). Exclusion Criteria: - Age < 14 years or > 80 years; - Pregnant or lactating female; - One of the following items occurred at the enrollment: (i) respiratory failure necessitating mechanical ventilation; (ii) liver failure: total bilirubin 10mg/dL and/or severe coagulation disorders; (iii) renal function failure: although adequate circulating blood and cardiac output, urine 0.5ml/kg\u00b7h, Cr or BUN 1.5 times normal elevation; - Intake of Chinese medicinal herbs during the past 2 weeks; - Refused to sign an informed consent form prior to study participation; - Unwilling and unable to comply with protocol request. To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection) |China, Beijing| |The Fifth Medical Center, Hospital of PD.||302 Military Hospital|[Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 30;:](/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRFjxK4BSg0VA6h9Ei4L3BUgWwNG0it.) [Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Cai JP, Chen H, Hui CK, Yuen KY. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15;395(10223):514-523. doi: 10.1016/S0140-6736(20)30154-9. Epub 2020 Jan 24.](/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRFjxK4BSg0jA6h9Ei4L3BUgWwNG0it.) [Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.](/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRFjxgFJxg48A6h9Ei4L3BUgWwNG0it.) Publications automatically this study by ClinicalTrials.gov Identifier (NCT Number): [Akhtar S, Das JK, Ismail T, Wahid M, Saeed W, Bhutta ZA. Nutritional perspectives for the prevention and mitigation of Nutr Rev. 2021 Feb 11;79(3):289-300. doi: 10.1093/nutrit/nuaa063.](/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRFRLgFtLK4RA6h9Ei4L3BUgWwNG0it.) Zhao P, Dong JH, Zhou YF, Yang G, Niu M, Zhao X, Jiang TJ, Bi JF, Xu Z, Zhang P, Wu D, Bai ZF, Guo YM, Yu SM, Sun YQ, Zhang ZT, Ding JB, Zhao PF, Song XA, Tang JY, He DC, Chen Z, Qin EQ, Wang RL, Xiao XH. Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial. Chin J Integr Epub 2020 a U.S. FDA-regulated Device Product:||No| | Pneumonia | COVID-19 Infections Respiratory Tract Infections Lung Diseases Respiratory Tract Diseases Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Virus Diseases Pneumonia, Viral Interferons Ritonavir Lopinavir | Interferon-alpha | Interferon-alfa-1b Antineoplastic HIV Protease Inhibitors Viral Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Inhibitors Immunologic Factors "}